Clinical Trials

Trial Name Description
ORZORA GYN Dr. S Welch
An Open-Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness ans Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Respons
R2810-ONC-1676 Dr. Stephen Welch
"not yet open" An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma.
CX.5 SHAPE GYN Dr. Prefontaine
A Randomized Phase III Trial Comparing Radical Hysterectomy And Pelvic Node Dissection vs. Simple Hysterectomy And Pelvic Node Dissection in Patients With Low-Risk Early-Stage Cervical Cancer
PRIMA GYN Dr. S. Welch
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Ariel 4 GYN Dr. S. Welch
Not open yet - A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
PHL-093 Dr. Stephen Welch
A Randomized, Placebo-Controlled, Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD1775 (MK1775) in Women with Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
OVC.1 Dr. Stephen Welch
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
PHL-086 GYN Dr. Stephen Welch
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer.
FORWARD 1 GYN Dr. S. Welch
A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) versus Investigator's Choice of Chemotherapy in Women with Folate Receptor positive Advanced Epithelial Ovarian Cancer, Primar
OVC.2 GYN Dr. Stephen Welch
"not yet open" A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or pr
C31004 GYN Dr. S. Welch
A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 inhibitor), MLN0128 + MLN1117 (a PI3K Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women with Advanced, Recurrent, or Persistent Endometrial Can

This information is updated by the Clinical Research Unit

LHSCResearch & Training

Last Updated August 3, 2007 | © 2007, LHSC, London Ontario Canada